Ping-Tao Tseng, Bing-Yan Zeng, Yen-Wen Chen, Chun-Pai Yang, Kuan-Pin Su, Tien-Yu Chen, Yi-Cheng Wu, Yu-Kang Tu, Pao-Yen Lin, Andre F Carvalho, Brendon Stubbs, Yutaka J Matsuoka, Dian-Jeng Li, Chih-Sung Liang, Chih-Wei Hsu, Cheuk-Kwan Sun, Yu-Shian Cheng, Pin-Yang Yeh, Yow-Ling Shiue
BACKGROUND: While Alzheimer's dementia (AD) has a prevalence as high as 3-32% and is associated with cognitive dysfunction and the risk of institutionalization, no efficacious and acceptable treatments can modify the course of cognitive decline in AD. Potential benefits of exogenous melatonin on cognition have been divergent across trials. OBJECTIVE: The current network meta-analysis (NMA) was conducted under frequentist model to evaluate the potential benefits of exogenous melatonin supplementation on overall cognitive function in participants with AD in comparison with other FDA-approved medications (donepezil, galantamine, rivastigmine, memantine, and Namzaric)...
April 20, 2022: Current Neuropharmacology